You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Harvard Business School
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,677,326

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,677,326 protect, and when does it expire?

Patent 6,677,326 protects RAYOS and is included in one NDA.

This patent has fifteen patent family members in seven countries.

Summary for Patent: 6,677,326
Title: Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
Abstract:The subject invention concerns a unit dose formulation comprising less than 2.5 mg of prednisolone or an equivalent, equipotent amount of another corticosteroid. One embodiment of a method of the invention concerns once daily administration of the unit dose formulation between midnight and 6 a.m. for the treatment of rheumatoid arthritis.
Inventor(s): Bardsley; Hazel Judith (Cambridge, GB), Bannister; Robin Mark (Essex, GB), Gilbert; Julian Clive (Essex, GB)
Assignee: Arakis, Ltd. (GB)
Application Number:10/263,044
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,677,326
Patent Claim Types:
see list of patent claims
Formulation; Use; Dosage form;

Drugs Protected by US Patent 6,677,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,677,326

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9905898Mar 15, 1999
United Kingdom0023220Sep 21, 2000

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Moodys
Dow
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.